Liliana B Menalled

Summary

Affiliation: PsychoGenics Inc
Country: USA

Publications

  1. pmc Knock-in mouse models of Huntington's disease
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York 10591, USA
    NeuroRx 2:465-70. 2005
  2. pmc Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York, United States of America
    PLoS ONE 5:e9793. 2010
  3. ncbi request reprint Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington's Disease
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York, United States of America
    PLoS ONE 9:e99520. 2014
  4. pmc Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York, United States of America
    PLoS ONE 7:e49838. 2012
  5. ncbi request reprint Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice
    Liliana B Menalled
    Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California 90095, USA
    J Neurosci 22:8266-76. 2002
  6. ncbi request reprint Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats
    Liliana B Menalled
    Department of Neurology, University of California at Los Angeles, Los Angeles, California 90095, USA
    J Comp Neurol 465:11-26. 2003
  7. ncbi request reprint Mouse models of Huntington's disease
    Liliana B Menalled
    Dept of Neurology, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095, USA
    Trends Pharmacol Sci 23:32-9. 2002

Detail Information

Publications7

  1. pmc Knock-in mouse models of Huntington's disease
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York 10591, USA
    NeuroRx 2:465-70. 2005
    ..This review describes the different knock-in models generated, the insight gained from them, and their value in the development and testing of prospective treatments of the disease...
  2. pmc Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York, United States of America
    PLoS ONE 5:e9793. 2010
    ..We were thus unable to confirm the previously reported benefits for these two drugs, and we discuss potential reasons for these discrepancies, such as the effects of husbandry and nutrition...
  3. ncbi request reprint Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington's Disease
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York, United States of America
    PLoS ONE 9:e99520. 2014
    ..Finally, no amelioration of the dysregulation of striatal and cortical gene markers was detected. We conclude that TG2 is not a valid therapeutic target for the treatment of HD. ..
  4. pmc Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175
    Liliana B Menalled
    PsychoGenics Inc, Tarrytown, New York, United States of America
    PLoS ONE 7:e49838. 2012
    ..These data suggest that the zQ175 knock-in line could be a suitable model for the evaluation of therapeutic approaches and early events in the pathogenesis of HD...
  5. ncbi request reprint Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice
    Liliana B Menalled
    Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California 90095, USA
    J Neurosci 22:8266-76. 2002
    ....
  6. ncbi request reprint Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats
    Liliana B Menalled
    Department of Neurology, University of California at Los Angeles, Los Angeles, California 90095, USA
    J Comp Neurol 465:11-26. 2003
    ..Because of their early behavioral anomalies and regionally specific pathology, these mice provide a powerful tool with which to evaluate the effectiveness of new therapies and to study the mechanisms involved in the neuropathology of HD...
  7. ncbi request reprint Mouse models of Huntington's disease
    Liliana B Menalled
    Dept of Neurology, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095, USA
    Trends Pharmacol Sci 23:32-9. 2002
    ..In this article, insights gained from mouse models towards the understanding of HD and the design of new therapeutic strategies are discussed...